文献速递药物不良反应与药物警戒

抗癫痫药物相关运动障碍:FDA不良事件报告系统的真实世界失衡分析

Movement disorders associated with antiseizure medications: A real-world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System.
PubMed 文献 · Br J Clin Pharmacol · 2023-07-18

本研究基于FDA不良事件报告系统数据库,提取26种已上市抗癫痫药物相关的不良药物反应,采用失衡分析法评估抗癫痫药物与运动障碍之间的关联,并绘制信号颜色量表图以识别潜在安全信号。共纳入1921例服用抗癫痫药物期间发生运动障碍的病例,女性患病率高于男性。拉莫三嗪和卡波西平表现出多种显著的运动障碍信号,左乙拉西坦和普瑞巴林与运动障碍的较早发生相关;通常剂量越高,运动障碍发生率越高。

要点

  • 拉莫三嗪和卡波西平与多种显著运动障碍信号相关。
  • 左乙拉西坦和普瑞巴林与运动障碍较早发生相关。
  • 通常抗癫痫药物剂量越高,运动障碍发生率越高。

核心结论

  • 运动障碍是抗癫痫药物引发的神经系统中最明显的不良药物反应。
  • 12种抗癫痫药物被认为诱发运动障碍的可能性较低。
  • 通过为癫痫患者选择合适的抗癫痫药物,可以减轻运动障碍的发生率。

研究设计与样本

  • 研究从FDA不良事件报告系统中提取26种已上市抗癫痫药物的所有不良药物反应进行分析。
  • 采用失衡分析法评估抗癫痫药物与运动障碍之间的关联,并创建信号颜色量表图以识别潜在安全信号。

主要发现

  • 共纳入1921例服用抗癫痫药物期间发生运动障碍的病例。
  • 女性运动障碍患病率高于男性。
  • 揭示了特定运动障碍与抗癫痫药物的关联,包括已知和未知的运动障碍如震颤、帕金森和瘫痪。
  • 拉莫三嗪和卡波西平表现出多种显著的运动障碍信号。
  • 左乙拉西坦和普瑞巴林与运动障碍的较早发生相关。

临床怎么用

  • 为癫痫患者选择抗癫痫药物时,应考虑药物诱发运动障碍的可能性,以减轻运动障碍的发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Patients with epilepsy often require long-term use of antiseizure medications (ASMs) to control their seizures. However, movement disorders (MDs) related to ASMs can significantly impact their quality of life. This study aims to analyse MDs related to ASMs in the Food and Drug Administration Adverse Event Reporting System database to provide recommendations for safe medication. METHODS: All adverse drug reactions associated with 26 marketed ASMs in Food and Drug Administration Adverse Event Reporting System were extracted for analysis. Disproportionality analyses were used to assess the association between ASMs and MDs, and signal colour scale maps were created to identify potential ASM-MD safety signals. RESULTS: A total of 1921 cases experienced MDs while taking ASMs were included. A higher prevalence of MDs was observed in females compared to males. The association between specific MDs with ASMs was revealed, including known and unknown MDs such as tremors, Parkinson and paralysis. Lamotrigine and carbamazepine exhibited multiple significant MDs, while levetiracetam and pregabalin were linked to the earlier onset of MDs. Generally, higher doses were linked to a higher incidence of MDs. CONCLUSION: MDs were the most obvious adverse drug reactions in the nervous system triggered by using ASMs. Fourteen drugs exhibited positive signals for MDs, including some not previously reported. Conversely, 12 ASMs were deemed to have a lower possibility of inducing MDs. The incidence of MDs can be mitigated by selecting appropriate ASMs for epileptic patients. These findings enhance our understanding of the relationship between ASMs and MDs.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhou J, Wei Z, Chen S, et al. Movement disorders associated with antiseizure medications: A real-world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2023. PMID: 37353394. doi:10.1111/bcp.15836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。